ERBB2 and inflammatory breast carcinoma: Beside estrogen and progesterone receptor (ER/PR) status of the human epidermal growth factor receptor 2 (HER2, ERBB2) is an important prognostic and predictive biomarker and is strongly expressed in 15–20% of newly diagnosed invasive BCs (IBC) [1–4].